The Bull Rankings scorecard — our quality-growth score is 50 / 100, built from three pillars scored 0–100: Quality 66, Growth 66, Value 29 (valuation is judged against sector peers). At today's price, our reverse-DCF read says the market is implicitly betting on free-cash-flow growth of about 20% a year next year, fading to 3% a year by year ten — a gauge of how much optimism is already in the stock.
The thesis
Emerson Electric Co. (EMR) is a solid industrial whose price already asks a lot. The Bull Rankings model assigns it a 50/100 quality‑growth score, with Quality 66 and Growth 66. Quality signals durable profitability and cash‑flow generation, while the weakest pillar, Value, indicates that the market has already priced in most upside. The sharpest argument for caution at $150.34 is that the stock is already priced for 20 %/yr free‑cash‑flow growth implied by the reverse‑DCF, while the company’s actual revenue growth is 4.8 % YoY on a profit margin of 13.8 %. In other words, the price assumes a sharp acceleration the business has yet to show.
What the business actually is
EMR’s revenue engine is built around three core segments. The Final Control arm delivers control valves, isolation valves, shut‑off valves, pressure relief valves, pressure safety valves, actuators, and regulators for process and hybrid industries under brands like Anderson Greenwood and Keystone. The Measurement & Analytical segment supplies intelligent instrumentation that measures physical properties, while the Discrete Automation segment focuses on automation solutions for manufacturing and industrial customers. These segments serve a global customer base across the Americas, Asia, the Middle East, Africa, and Europe, positioning EMR as a technology‑driven industrial machinery provider that blends hardware with software.
Why it can (or can't) keep compounding
The moat lies in high operating leverage and recurring revenue. With a profit margin of 13.8 % and a free‑cash‑flow of $3.5 b, EMR demonstrates the ability to convert sales into cash efficiently. The company’s debt‑to‑equity of 0.68 keeps leverage manageable, while the beta of 1.23 shows that the stock’s volatility is only modestly higher than the market. The model’s Raising its dividend signal reinforces the narrative that EMR is confident in its cash‑flow stability and is willing to share excess with shareholders. Competitors struggle to replicate EMR’s integrated hardware‑software platform; the breadth of its product lines and the depth of its brand portfolio create switching costs that are hard to erode quickly.
The valuation question
At a P/E of 33 and a PEG of 1.76, EMR trades at a premium that reflects growth expectations. The reverse‑DCF indicates that the current price implies 20 %/yr free‑cash‑flow growth (in year one, slowing to 3% a year by year ten). Compared to the 4.8 % revenue growth reported for FY YoY, the implied growth is dramatically higher. This gap suggests that the market is already pricing in a significant acceleration of cash‑flow generation—perhaps from new product launches or expanding automation deployments. If the company can lift free‑cash‑flow growth to match the implied 20 %, the stock would be fairly valued; if it stalls, the premium evaporates. The analyst consensus 1‑yr target of $171.81 and a target range of $104–$205 further imply that analysts see room for upside, but only if the company sustains its quality metrics.
The bear case
The most compelling skeptic points to Value as the weakest pillar. A Value score of 29 indicates that the market already values EMR at a high multiple relative to peers. If the company’s profit margin or free‑cash‑flow were to decline, the premium would crumble. A concrete signal that would confirm this scenario is a drop in free‑cash‑flow below $3.5 b or a margin compression below 13.8 %. Such a shift would erode the quality advantage that justifies the current price and would likely trigger a sell‑off.
What would change our mind
- Free‑cash‑flow falling below $3.5 b – a clear erosion of the company’s ability to fund growth and return capital to shareholders.
- Profit margin slipping below 13.8 % – a sign that competitive pressure or cost inflation is eating into the high‑margin business.
- Debt‑to‑equity rising above 0.68 – increased leverage could constrain future investment and raise risk.
If any of these thresholds are breached, the Bull Rankings model would downgrade the Quality pillar, and the current price would look even harder to justify.